Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4050 | Oxindole |
| 1. Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development. | |
| BCN4057 | Hydrocinnamic acid |
| 1. Hydrocinnamic acid inhibits the currents of WT and SQT3 syndrome-related mutants of Kir2.1 channel. | |
| BCN4059 | Cyclo(Gly-L-Pro) |
| Cyclo(Gly-(L)-Pro) shows immunostimulatory properties. Cyclo(Gly-l-Pro) exhibits potent inhibition of TNF-α release with the IC50 values of 4.5 ug/mL, respectively, it also exhibits significant diminution of IL-1β and IL-6 mRNA-expression levels and NO production. | |
| BCN4071 | Mirabijalone D |
| 1. Mirabijalone D is a non-competitive inhibitor based on the Dixon plot. 2. Mirabijalone D inhibits Aβ1–42 production by 43.7% in APPSW-N2a cells. | |
| BCN4099 | beta-Amyrin palmitate |
| 1. Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity. 2. Beta-Amyrin palmitate, like mianserin and imipramine, reduces the duration of immobility of mice significantly in a dose-dependent manner (5, 10 and 20 mg kg-1); (1)Beta-Amyrin palmitate or mianserin elicits a dose-related reduction in locomotor activity of mice and antagonizes locomotor stimulation induced by methamphetamine, imipramine increases locomotor activity and potentiates methamphetamine-induced hyperactivity; (2)Beta-Amyrin palmitate shows no effect on reserpine-induced hypothermia, whilst mianserin (10 mg kg-1) and imipramine (10 and 20 mg kg-1) antagonizes the reserpine-induced effect; (3)Beta-amyrin palmitate has similar properties in some respects to mianserin and might possess a sedative action. | |
